Navigation Links
Pitt: Targeted oxidation-blocker prevents secondary damage after traumatic brain injury
Date:8/26/2012

PITTSBURGH, Aug. 26, 2012 Treatment with an agent that blocks the oxidation of an important component of the mitochondrial membrane prevented the secondary damage of severe traumatic brain injury and preserved function that would otherwise have been impaired, according to a research team from the University of Pittsburgh School of Medicine, Graduate School of Public Health and Department of Chemistry in a report published online today in Nature Neuroscience.

Annually, an estimated 1.7 million Americans sustain a traumatic brain injury (TBI) due to traffic accidents, falls, assaults and sports participation, said the study's senior author Hlya Bayιr, M.D., associate professor, Department of Critical Care Medicine, University of Pittsburgh School of Medicine. She added that 52,000 of those injured die, and 85,000 are left with significant disability.

"We don't yet have a specific therapy for TBI, but can provide only supportive care to try to ease symptoms," Dr. Bayιr said. "Our study drug shows promise as a neuroprotective agent that might help address this important public health problem."

For the study, the research team conducted a global assessment of all the phospholipids in rat brain cells. This revealed that damage from TBI was nonrandom and mostly involved cardiolipin, a phospholipid that is found in the membranes that form mitochondria, the cell's powerhouse. They noted that in the healthy animal, only 10 of the 190 cardiolipin species were modified by oxygen, but after a brain injury, the number of oxidized species rose many-fold.

The researchers then developed an agent, called XJB-5-131, which can cross the blood-brain barrier and prevent the oxidation of cardiolipin. Using an established research model of severe TBI, the agent or a placebo was injected into the bloodstream of rats five minutes and again 24 hours after head injury.

In the weeks that followed, treated animals performed a
'/>"/>

Contact: Anita Srikameswaran
SrikamAV@upmc.edu
412-578-9193
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. First targeted nanomedicine to enter human clinical studies
3. Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer
4. Dana-Farber: Study reports first success of targeted therapy in type of non-small cell lung cancer
5. Inflammatory pathway spurs cancer stem cells to resist HER2-targeted breast cancer treatment
6. Killer infections targeted by hospital study
7. Lower risk of serious side-effects in trials of new targeted drugs
8. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
9. New drug prevents spread of human prostate cancer cells
10. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
11. Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... LunaDress.co.uk has updated its blog to provide professional shopping tips on ... models at LunaDress.co.uk come with big discounts, up to 80 percent ... turn out to be a most exciting memory and can show ... surprise to a wedding. On the updated fashion blog, ladies can ... a big day . , Going out with friends to a ...
(Date:12/25/2014)... 24, 2014 (HealthDay News) -- Among early stage breast ... than half of one percent will eventually develop leukemia ... reveals. The finding comes from a review of ... and 2007, and it suggests that the risk for ... experts had previously thought. "The frequency of bone ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... AMERIGROUP,Corporation (NYSE: AGP ) today announced that ... Conference on November 13 in Phoenix,Arizona., A live ... at 4:00 p.m. Eastern Time, can be accessed on ... A replay will,be available for 30 days, and can ...
... LOS ANGELES, Oct. 30 Members of SEIU ... collective bargaining,agreements that will make improvements for hundreds ... several California nursing homes., In all, seven ... wage increases of $1.50/hr over three years, employer ...
... age of disease onset and nerve cell death , , ... genes may be linked to the most common form ... team, from Massachusetts General Hospital-MassGeneral Institute for Neurological Disease ... families with a history of the devastating neurological disorder. ...
... Medical, Inc.,(Nasdaq: ATSI ), manufacturer and marketer ... it has received U.S. Food,and Drug Administration (FDA) ... http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), This is the Company,s ... market. Based on the precept that ,Form Follows ...
... WellPoint,s commercial marketing,team was awarded a silver ... its innovative campaign, "Ecosphere -- Simple is more ... Awards competition is the only international,award that honors ... response results., WellPoint,s campaign, conducted through its ...
... AGA Medical Holdings ("AGA,Medical", "AGA") announced today its ... Court in the Netherlands related to a proceeding,brought ... lawsuit,sought invalidity and/or non-infringement declarations related to AGA,Medical,s ... its European patents,for intravascular occlusion devices and the ...
Cached Medicine News:Health News:Scientists Spot 4 New Alzheimer's Genes 2Health News:ATS Medical Announces FDA Approval of the ATS 3f Aortic Bioprosthesis 2Health News:ATS Medical Announces FDA Approval of the ATS 3f Aortic Bioprosthesis 3Health News:ATS Medical Announces FDA Approval of the ATS 3f Aortic Bioprosthesis 4Health News:WellPoint Awarded Prestigious International Marketing Award 2Health News:AGA Medical to Appeal Ruling by Dutch Court in Lawsuit With Occlutech GmbH 2
(Date:12/24/2014)... 24, 2014  Actavis plc (NYSE: ... received a complete response letter from the U.S. ... Drug Application (NDA) for the fixed-dose combination (FDC) ... hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... the receipt of a complete response letter, Actavis ...
(Date:12/24/2014)... -- The International Trade Commission (ITC) issued its final decision in ... a notice issued on December 23, the ITC ruled in ... humidifier was invalid. BMC President, James Xu ... excited with the ITC,s decision in this case. This victory ... the very beginning on the key patents in the case. ...
(Date:12/24/2014)... -- PuraMed BioScience®, Inc., (OTC Pink: PMBS), a researcher, ... products, announced it received the initial funding to begin ... relief product, for planned distribution to 1,000 medical and ... Washington State , and ... Advanced headache relief gel formulation completed, PuraMed BioScience has ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... with Turner ... ... Norditropin(R) (somatropin [rDNA origin] injection) received,approval from the U.S. Food and ... with Turner syndrome. Turner,syndrome is a rare chromosomal condition caused by ...
... NeurogesX, Inc.,(Nasdaq: NGSX ) announced today ... second Phase 3 clinical trial of its lead ... sensory polyneuropathy,(HIV-DSP). NGX-4010 is a dermal patch designed ... trials demonstrated that a,single, 30- or 60-minute treatment ...
Cached Medicine Technology:Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 2Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 3Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 4Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 5Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 6NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 2NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 3NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy 4
... Blot is an FDA approved confirmatory test ... fluid sample. Repeatedly reactive results of initial ... HIV-1 Microelisa System can be confirmed with ... the same OraSure sample. The OraSure HIV-1 ...
Prognosis / Patient Management. HIV-1 Viral Load Assay. NucliSens HIV-1 QT covers the entire dynamic range of viral load testing from a single patient sample, without reflex testing or thermalcycli...
... genome of the Human Immunodeficiency Virus (HIV-1) ... in response to anti-viral drug treatment. Some ... render the virus resistant to the action ... the treatment.,The detection of mutations in HIV-1 ...
EIA for Donor Screening. Synthetic peptide Enzyme Immunoassay (EIA) for the detection of antibodies to Human Immunodeficiency Virus Types 1 and/or 2,(HIV-1 and HIV-2) in human serum, plasma or ca...
Medicine Products: